Kornimate/medical-research-clean huggingface dataset:
comparison of autologous prf, 1% alendronate and 1.2% atorvastatin gel in chronic periodontitis treatment

Conditions: Chronic Periodontitis

Summary: the present study is designed as a single-centre, randomized, controlled clinical trial to evaluate and compare the clinical efficacy of autologous prf, 1% alendronate (aln) and 1.2% atorvastatin (atv) gel placement with open flap debriedement in treatment of intrabony defects in patients with chronic periodontitis.

background: platelet-rich fibrin (prf) is a second-generation platelet concentrate which releases various growth factors that promote tissue regeneration. alendronate and atorvastatin are known to inhibit osteoclastic bone resorption and were proposed to have osteostimulative properties by causing osteoblast differentiation in vivo and in vitro as shown by an increase in matrix formation. the aim of the present study is to evaluate and compare the efficacy of autologous prf, 1% alendronate and 1.2% atorvastatin gel placement with open flap debriedement in treatment of intrabony defects in patients with chronic periodontitis. methods: 120 cp subjects with ibd ≥3 mm deep and probing depth (pd) ≥5 mm, following scaling and root planing (srp), were categorized into four treatment groups: 1) ofd 2) ofd with prf 3) ofd with 1% aln gel and 4) ofd with 1.2% atv gel. clinical parameters including site specific plaque index (pi), modified sulcus bleeding index (msbi), probing depth (pd) and relative attachment level (ral) as well as percentage radiographic intrabony defect depth reduction (ddr) were recorded at baseline before surgery and 9 months post-operatively.

Eligibility criteria:
inclusion criteria: * systemically healthy patients with pds ≥5mm or cals ≥4 to 6mm and vertical bone loss ≥3 mm on intraoral periapical radiographs with no history of periodontal therapy or use of antibiotics in the preceding 6 months were included exclusion criteria: * patients with a known systemic disease * known or suspected allergy to the aln/ bisphosphonates or atv/statin group * on systemic aln/ bisphosphonates or atv/statin group * with aggressive periodontitis * who used tobacco in any form * alcoholics * immunocompromised patients * and pregnant or lactating females were excluded from the study
neurological blood-based biomarkers and cognitive disorders in critically ill survivors.

Conditions: Intensive Care Unit Syndrome; Post-intensive Care Syndrome; Cognitive Disorder

Summary: cognitive disorders are common after intensive care. currently, their diagnosis is based on clinical tests. the investigators plan to study the relationship between different neurological blood biomarkers (cytokines, s100β protein, neuron specific enolase, total tau protein and neurofilament light chain) and the occurrence of cognitive disorders during the three months following intensive care discharge.


Eligibility criteria:
inclusion criteria: * anticipated icu stay of at least 7 days for sepsis, acute respiratory distress syndrome, severe burns * french speaking exclusion criteria: * hearing loss or blindness * mental retardation * known cognitive disorders or dementia * icu admission for neurological disease * refusal
safety study of pegylated interferon lambda plus single or 2 direct antiviral agents with ribavirin

Conditions: Hepatitis C

Summary: substudy c: the purpose of this substudy is to determine whether lambda combined with ribavirin and daclatasvir for 12 weeks is efficacious in treatment naïve subjects with genotype 1b chronic hcv infection


Eligibility criteria:
inclusion criteria: * chronic hepatitis c, genotype 1 * hcv rna \>100,000 iu/ml at screening; * seronegative for human immunodeficiency virus (hiv) and hepatitis b surface antigen (hbsag); * liver biopsy within prior 2 years; subjects with compensated cirrhosis can enroll and will be capped at approximately 10% exclusion criteria: * any evidence of liver disease other than hcv; * co-infection with hiv; * diagnosed or suspected hepatocellular carcinoma; * medical history or laboratory value abnormalities that would prohibit the use of pegylated interferon alpha-2a or ribavirin
impacts of subsidized ridesharing on drunk driving, alcohol consumption, and mobility

Conditions: Driving Drunk; Alcohol Drinking

Summary: the purpose of this research study is to understand people's alcohol use in public places and their risks for harm. the overall goal of this study is to test the effects of subsidized ridesharing as an intervention to reduce self-reported alcohol-impaired driving, along with alcohol consumption and changes to mobility.

motor vehicle crashes are the leading cause of death for people aged 13-25 years in the us, and approximately 31% of all fatal crashes involved some alcohol use. several peer-reviewed studies have found that ridesharing was associated with fewer alcohol-involved crashes and dui arrests. theories of behavioral economics provide a clear theoretical mechanism by which ridesharing will reduce alcohol-involved motor vehicle crashes compared to other private transportation. however, while ridesharing may be an effective intervention to reduce alcohol-involved crashes, it may simultaneously increase alcohol consumption. this study will assess the impacts of subsidized ridesharing on impaired driving, alcohol consumption, and mobility. participants will be randomized to either receive a rideshare voucher or an online shopping voucher, and effects on alcohol impaired driving and alcohol consumption will be measured. a gps sub-group will use a custom smartphone application for gps tracking to measure mobility.

Eligibility criteria:
inclusion criteria: * ≥ 21 years old * reside in a study city * have a driver's license * have access to a motor vehicle * have consumed alcohol in a bar in the last 30 days * own a smartphone * read english exclusion criteria: * non-english speaking participants

Keywords: drunk driving ridesharing alcohol drinking driving under the influence (dui)
treatment of supracondylar fractures closed reduction and circular ring external fixation versus open reduction and internal fixation

Conditions: Supracondylar Humerus Fractures

Summary: patients treated with circular external fixation will have better outcomes (as measured by range of motion (rom), alignment, outcome surveys) than those treated with open reduction and internal fixation (orif).

the purpose of this study is to compare patients who undergo orif versus circular external fixation for supracondylar humerus fractures in children ages 12-18. we are asking parental permission to collect information about their child's injury, x-rays, obtain rom measures, collect input from questionnaires, and review other medical information relating to the injury. the study is not about randomizing subjects to treatment, rather we are asking permission to keep track of the decisions that are made about our population's treatment and how it impacts their recovery. the eligibility criteria is subject's between 12 and 18 years, if supracondylar/periarticular humerus fracture needed operative fixation, and the fracture is unable to be treated with percutaneous skeletal fixation. patients will be excluded if they have had a previous elbow injury, osteogenesis imperfecta or another fragile bone disease, elbow stiffness from another cause, or any pre-existing arm weakness. the outcome measures all enrolled subjects will complete are the quickdash and the pediatric and adolescent outcomes instruments (podci). the quickdash is a shortened version of the dash (disabilities of the arm, shoulder and hand) outcome measure which is intended to measure symptoms and functions in people with musculoskeletal disorders of the upper limb. the quickdash is valid and reliable and is used for clinical and research purposes. the podci is designed to assess patients overall health, pain and ability to participate in normal daily activities in patients under 19 years of age. we will only distribute both questionnaires to the subjects and we are not collecting parent perception.

Eligibility criteria:
inclusion criteria: * 12 and 18 years old * supracondylar/periarticular humerus fracture needed operative fixation * fracture is unable to be treated with percutaneous skeletal fixation. exclusion criteria: * any previous elbow injury * osteogenesis imperfecta or another fragile bone disease * elbow stiffness from another cause * any pre-existing arm weakness.

Keywords: supracondylar humerus fractures, external fixation, open reduction, and internal fixation.
optimization of tkis treatment and quality of life in ph+ cml patients ≥60 years in deep molecular response

Conditions: Leukemia, Chronic Myeloid

Summary: in this phase iii clinical randomized study, "fixed" intermittent administration (one month on/one month off) of tkis (control arm), will be compared with "progressive" intermittent administration (one month on/one month off for the 1st year; one month on/two months off for the 2nd year; one month on/three months off for the 3rd year) (experimental arm). imatinib (glivec), or nilotinib (tasigna), or dasatinib (sprycel) will be given intermittently at the same daily dose that was given daily at the time of the enrollment . chronic phase ph+ cml patients in stable major molecular response (mr3.0 or mr4.0) after ≥2 years of standard treatment with im, nil, or das will be randomized 1:1 to receive "fixed" interim or "progressive" interim. randomization will be stratified by type of tki (im, nil, or das,) and by depth of molecular response (mr3.0or mr4.0). the study is aimed to evaluate if a progressive increase of intermittent treatment discontinuation until 3 months is able to improve qol outcomes with respect to "fixed" intermittent administration of tkis (control arm) and to maintain mr3.0 / mr4.0 molecular response. patients' self reported eortc qlq-c30 outcome measure will be assessed throughout the three years follow up period. the qol results in this trial will be presented in accordance with high methodological quality criteria for documenting patient-reported outcomes (pro) data in rcts, including the consort pro recommendations. furthermore, the study could give additional clinical and biological information to optimize tkis therapy in elderly.


Eligibility criteria:
inclusion criteria: 1. patients with a confirmed diagnosis of ph+ cml in cp 2. age ≥ 60 years old 3. stable mr3.0/ mr4.0 after at least 2 years of treatment with standard (daily administration) im, nil, or das therapy; the stability of molecular response will be documented by at least 3 consecutive molecular analyses over the last 12 months. 4. having completed the qol baseline evaluation (i.e., before randomization) 5. written informed consent prior to any study procedures exclusion criteria: 1. patients with ph+ cml in accelerated/blastic phase (ap/bp), or in late cp previously treated (i.e. ifnalpha+/- low dose ara-c, hydroxurea, allogeneic stem cell transplantation, etc) 2. age \< 60 years old 3. less than 2 years of treatment with standard (continuous administration) im, nil or das therapy 3. absence of stable mr3.0/mr4.0 as documented by at least 3 consecutive molecular analyses over the last 12 months 4. no written informed consent prior to any study procedures. 5. having any kind of psychiatric disorder or major cognitive dysfunction hampering a qol evaluation (as judged by the physician).
the effect of preoperative counseling on emergence agitation in patients candidate for nasal surgeries

Conditions: Postoperative Agitation

Summary: emergence agitation is a post anesthetic phenomenon that develops in the early phase of general anesthesia recovery,the aim of our study to investigate the effect of preoperative educational counselling of the patient undergoing nasal surgery on emergence agitation .

while its pathogenesis remains unclear, previous studies reported that ent (ear, nose, and throat) surgical procedures have a higher incidence of emergence agitation in both adults and children. especially, our clinical impression is that nasal surgical patients admitted to the postbanesthesia care unit (pacu) have suffered emergence agitation more frequently than other surgical patients, possibly due to a sense of suffocation during emergence from anesthesia. preoperative counselling and repeated verbal stimulation of orientation may serve as a simple and easily applicable strategy to reduce emergence agitation after general anaesthesia . there have been studies looking into the effect of pre-operative counselling on individual aspects internationally like anxiety, bmi, serum cholesterol , length of stay , pain .( six trials were identified and have produced conflicting findings. some trials have demonstrated the effects of preoperative education on improving physical and psychosocial recovery of cardiac patients, while others found no evidence that patients' anxiety is reduced or of any effect on pain or hospital stay) . to our knowledge there was no study investigating the impact of preoperative counselling on postoperative agitation following nasal surgeries, the aim of our study to investigate the effect of preoperative educational counselling of the patient undergoing nasal surgery on emergence agitation .

Eligibility criteria:
inclusion criteria: * both genders. * patients undergoing nasal surgery * american society of anesthesiologist (asa) i or ii physical status. * between 18 and 65 years of age. exclusion criteria: * ● patients with communication difficulties. * asa ⅲ and ⅳ patients. * mentally retarded patients. * in-ability to postpone anti-coagulation medications. * central or peripheral neurological disease. * drug or alcohol abuse. * localized infection at nose. * bleeding disorder (platelets count less than 100,000 or inr more than 1.4)

Keywords: agitation counseling nasal surgeries
q-poc sars-cov-2 assay covid-19 clinical evaluation

Conditions: COVID-19

Summary: q-poc sars-cov-2 moderate complexity pcr test performance evaluation

the q-poc sars-cov-2 assay is a real-time pcr test intended for use on the q-poc instrument for the qualitative detection of nucleic acids from severe acute respiratory syndrome coronavirus 2 (sars-cov-2), in nasal mid-turbinate swabs (mtsw) obtained from individuals suspected of covid-19 by their healthcare provider. testing is limited to laboratories certified under the clinical laboratory improvement amendments of 1988 (clia), 42 u.s.c. §263a, that meet requirements to perform high complexity or moderate complexity tests. the q-poc sars-cov-2 assay is intended for use by laboratory personnel who have received specific training on the use of the q-poc sars-cov-2 assay in conjunction with the q-poc instrument (q29001).

Eligibility criteria:
inclusion criteria: * participants must be over the age of 18 years. * participants must present with symptoms indicative of sars-cov-2 infection, within 0-5 days of symptom onset. * participants must have capacity to give informed consent. exclusion criteria: * participant is under the age of 18 years. * participant does not have symptoms of sars-cov-2 infection. * participant lacks capacity to give informed consent.
role of calcium binding protein s100a12 in diagnosis and prognosis of kawasaki disease

Conditions: Diagnoses Disease

Summary: recent studies showed that the value of c100a12 increased in children with kawasaki disease, and decreased rapidly after treatment with gamma globulin. in kawasaki disease with coronary artery dilatation, s100a12 levels are elevated in the acute phase of kawasaki disease and continue for some time in the convalescence phase before gradually decreasing. however, the number of patients included in previous studies was small and the follow-up time was short. in this study, 100 children with kawasaki disease who were admitted to wuhan children's hospital, jingzhou first people's hospital and renhe hospital affiliated to china three gorges university from december 2021 to december 2023 were selected as the research objects, and 100 children with healthy physical examination were selected as the control group during the same period. to investigate whether s100a12 increased significantly in the acute phase of kawasaki disease compared with a healthy control group. to study whether s100a12 value increased rather than decreased in kawasaki disease that did not respond to gamma globulin treatment after gamma globulin treatment. at the same time, to study whether the increase of s100a12 in kawasaki disease convalescence indicates coronary aneurysm.

s100a12 was determined using the elisa kit and according to the instructions.

Eligibility criteria:
inclusion criteria: ▪diagnostic criteria of kawasaki disease revised by the american heart association in 2017 exclusion criteria: * scarlet fever * drug allergy syndrome * stevens-johnson syndrome * toxic shock syndrome * adenovirus infection * epstein-barr(eb) virus infection
treatment period and long-term efficacy of functional electrical stimulation (fes) on sleep bruxism

Conditions: Bruxism

Summary: to investigate the effect of the treatment with grindcare® on the muscles- and jaw symptoms and at the jaw muscle activity during sleep.


Eligibility criteria:
inclusion criteria: * signed and dated icf * 18 years or older * fulfill the rdc-criteria for myofascial tmd diagnose (group 1a or 1b) exclusion criteria: * contraindication of concommitant diseases for the study judged by investigator * patients who are using occlusal splints in the treatment period.

Keywords: bruxism
repetitive transcranial magnetic stimulation with double cone coil in chronic tinnitus

Conditions: Chronic Tinnitus

Summary: transcranial magnetic stimulation is used to modulate both the auditory neural pathways contributing to the perception of phantom sounds, and the regulatory neural network responsible for the generation of the individual amount of suffering caused by chronic tinnitus.

tinnitus is the phantom auditory perception of sound in the absence of an external or internal acoustic stimulus. it is a frequent problem which can interfere significantly with the ability to lead a normal life. treatment remains difficult. most available therapies focus on habituation rather than treating the cause. tinnitus has been shown to be generated in the brain, as a result of functional reorganization of auditory neural pathways and tonotopic maps in the central auditory system. low-frequency rtms applied to the temporoparietal areas has been investigated for the treatment of hyperexcitability disorders such as auditory hallucinations and tinnitus. pilot data indicate that taking into account affective components of the multiple overlapping neural networks responsible for the generation of a bothersome subjective tinnitus might enhance the efficacy of repetitive transcranial magnetic stimulation (rtms) treatment in chronic tinnitus. a newly developed coil, the so-called double cone coil will be examined with regard to feasibility, safety and clinical efficacy in patients suffering from chronic tinnitus in a controlled pilot trial.

Eligibility criteria:
inclusion criteria: * diagnosis of bothersome, subjective chronic tinnitus * duration of tinnitus more than 6 months exclusion criteria: * objective tinnitus * treatable cause of the tinnitus * involvement in other treatments for tinnitus at the same time * clinically relevant psychiatric comorbidity * clinically relevant unstable internal or neurological comorbidity * history of or evidence of significant brain malformation or neoplasm, head injury * cerebral vascular events * neurodegenerative disorder affecting the brain or prior brain surgery; * metal objects in and around body that can not be removed * pregnancy * alcohol or drug abuse * prior treatment with tms

Keywords: rtms repetitive transcranial magnetic stimulation chronic tinnitus subjective tinnitus double cone coil
an extension study of lirentelimab in eosinophilic gastritis and/or eosinophilic duodenitis (formerly referred to as eosinophilic gastroenteritis)

Conditions: Eosinophilic Gastritis; Eosinophilic Duodenitis

Summary: this is a phase 3, open-label, extension study to assess the long term efficacy and safety of lirentelimab given monthly.


Eligibility criteria:
key inclusion criteria: 1. provide written informed consent. 2. completed study ak002-016, defined as having received 6 infusions of study drug and followed through day 176 (±3) or completed study ak002-012, defined as having received the cohort-appropriate amount of doses and followed for 5 months after last dose of study drug. 3. if patient is on pre-existing dietary restrictions, willingness to maintain those restrictions, throughout the study. 4. able and willing to comply with all study procedures. 5. female patients must be either post-menopausal for at least 1 year or surgically sterile (tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 3 months, or if of childbearing potential, have a negative pregnancy test and agree to use dual methods of contraception, or abstain from sexual activity until the end of the study, or for 120 days following the last dose of study drug, whichever is longer. 6. male patients with female partners of childbearing potential must agree to use a highly effective method of contraception until the end of the study or for 120 days following the last dose of study drug, whichever is longer. all fertile men with female partners of childbearing potential should be instructed to contact the investigator immediately if they suspect their partner might be pregnant at any time during study participation. key exclusion criteria: 1. known hypersensitivity to any constituent of the study drug. 2. any disease, condition (medical or surgical), or cardiac abnormality, which, in the opinion of the investigator, would place the patient at increased risk. 3. planned or expected vaccination with live attenuated vaccines during the treatment period, or vaccination expected within 5 half-lives (4 months) of ak002 administration. 4. women who are pregnant, breastfeeding, or planning to become pregnant while participating in the study. 5. any other reason that, in the opinion of the investigator or medical monitor, makes the patient unsuitable for enrollment.
sodium glucose co-transporter 2 (sglt2) and stemi

Conditions: Heart Attack; Enlarged Heart

Summary: the purpose of the research is to determine whether a class of medication called sglt2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (mri) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac mri and clinic visit at six months. this is a single center study.


Eligibility criteria:
inclusion criteria: * patients with their first stemi (\>18 years) who underwent successful primary pci and able to give informed consent * at least mild lv dysfunction (lvef \< 50%) on echocardiogram, cmri or left ventriculargram following pci * infarct size that is \> 10% of lv mass * the presence of mvo that is \> 10% of infarct size exclusion criteria: * contraindication to cardiac mri * life expectancy \< 1 year * previous cabg or valve surgery * previous stemi * pregnant or planning to become pregnant or lactating women * cardiogenic shock (not resolved) * atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding pvcs) * gfr\<30 ml/min/1.73m2 or end-stage renal disease on dialysis * type 1 diabetes mellitus or history of diabetic ketoacidosis * type i or ii diabetes with insulin use * prior intolerance of sglt2 inhibitors * current use of sglt2 inhibitors (randomized patients only) * contraindications to gadolinium

Keywords: dapagliflozin sodium glucose co-transporter 2